Oxaliplatin
Eloxatin (oxaliplatin) is a small molecule pharmaceutical. Oxaliplatin was first approved as Eloxatin on 2002-08-09. It is used to treat colorectal neoplasms, ovarian neoplasms, testicular neoplasms, and urinary bladder neoplasms in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| digestive system diseases | D004066 |
| urogenital diseases | D000091642 |
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Eloxatin (generic drugs available since 2009-08-07)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| oxaliplatin | ANDA | 2023-04-12 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9263 | Injection, oxaliplatin, 0.5 mg |
Clinical
Clinical Trials
1388 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 72 | 234 | 81 | 9 | 14 | 367 | ||
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 32 | 158 | 57 | 2 | 10 | 235 |
| Neoplasms | D009369 | C80 | 64 | 32 | 10 | 1 | 2 | 102 | |
| Adenocarcinoma | D000230 | 20 | 58 | 21 | 1 | 5 | 90 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 10 | 29 | 14 | 1 | 5 | 53 |
| Colonic neoplasms | D003110 | C18 | 14 | 22 | 15 | 2 | 3 | 50 | |
| Neoplasm metastasis | D009362 | EFO_0009708 | 3 | 15 | 3 | 1 | 2 | 22 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 52 | 89 | 14 | — | 2 | 131 |
| Rectal neoplasms | D012004 | 26 | 70 | 17 | — | 7 | 106 | ||
| Esophageal neoplasms | D004938 | C15 | 19 | 52 | 4 | — | 1 | 64 | |
| Cholangiocarcinoma | D018281 | C22.1 | 5 | 22 | 6 | — | 1 | 31 | |
| Biliary tract neoplasms | D001661 | C24.9 | 4 | 25 | 3 | — | 1 | 30 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 7 | 16 | 7 | — | — | 24 | |
| Pancreatic ductal carcinoma | D021441 | 10 | 13 | 2 | — | — | 22 | ||
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | 10 | 12 | 3 | — | 1 | 21 |
| Non-small-cell lung carcinoma | D002289 | 7 | 13 | 1 | — | — | 19 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 10 | 10 | 1 | — | — | 18 |
Show 27 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 6 | 14 | — | — | — | 19 |
| Peritoneal neoplasms | D010534 | 9 | 3 | — | — | 2 | 13 | ||
| Head and neck neoplasms | D006258 | — | 12 | — | — | 1 | 13 | ||
| Squamous cell carcinoma | D002294 | 2 | 6 | — | — | — | 7 | ||
| Appendiceal neoplasms | D001063 | EFO_0003880 | C18.1 | 6 | 1 | — | — | — | 7 |
| Bile duct neoplasms | D001650 | 3 | 5 | — | — | — | 6 | ||
| Germ cell and embryonal neoplasms | D009373 | 2 | 4 | — | — | — | 6 | ||
| Nasopharyngeal neoplasms | D009303 | 1 | 5 | — | — | — | 6 | ||
| Triple negative breast neoplasms | D064726 | 2 | 2 | — | — | 1 | 5 | ||
| Acinar cell carcinoma | D018267 | 3 | 2 | — | — | — | 5 |
Show 69 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphomatoid granulomatosis | D008230 | C83.8 | 2 | — | — | — | — | 2 | |
| Hematologic neoplasms | D019337 | 1 | — | — | — | — | 1 | ||
| Castration-resistant prostatic neoplasms | D064129 | 1 | — | — | — | — | 1 | ||
| Primary myelofibrosis | D055728 | D47.4 | 1 | — | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 | |
| Myelomonocytic leukemia chronic | D015477 | C93.1 | 1 | — | — | — | — | 1 | |
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | C92.2 | 1 | — | — | — | — | 1 | |
| Myeloid leukemia chronic-phase | D015466 | 1 | — | — | — | — | 1 | ||
| Thrombocytosis | D013922 | D75.83 | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OXALIPLATIN |
| INN | oxaliplatin |
| Description | Oxaliplatin, sold under the brand name Eloxatin among others, is a cancer medication (platinum-based antineoplastic class) used to treat colorectal cancer. It is given by injection into a vein.
|
| Classification | Small molecule |
| Drug class | antineoplastics (platinum derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O |
Identifiers
| PDB | — |
| CAS-ID | 61825-94-3 |
| RxCUI | 32592 |
| ChEMBL ID | CHEMBL414804 |
| ChEBI ID | — |
| PubChem CID | 11947679 |
| DrugBank | DB00526 |
| UNII ID | 04ZR38536J (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 51,272 documents
View more details
Safety
Black-box Warning
Black-box warning for: Oxaliplatin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
49,937 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more